Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Trop Med Hyg ; 74(4): 591-2, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16606989

ABSTRACT

Sodium stibogluconate (Pentostam(R); GlaxoSmithKline) is a pentavalent antimonial compound used in the treatment of leishmaniasis, which has an association with reactivation of varicella zoster virus (VZV). We report the first known case of an immunocompetent adult who developed VZV aseptic meningitis and dermatomal herpes zoster during treatment with sodium stibogluconate.


Subject(s)
Antimony Sodium Gluconate/adverse effects , Antiprotozoal Agents/adverse effects , Encephalitis, Varicella Zoster/etiology , Leishmania major/isolation & purification , Leishmaniasis, Cutaneous/diagnosis , Leishmaniasis, Cutaneous/drug therapy , Adult , Animals , Diagnosis, Differential , Herpes Zoster , Humans , Leishmaniasis, Cutaneous/pathology , Male , Skin Diseases, Viral/etiology
3.
Ann Epidemiol ; 12(6): 402-9, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12160599

ABSTRACT

PURPOSE: Risk factors, sites, and mortality of hospitalized cytomegalovirus (CMV) disease in renal transplant recipients have not been studied in a national population. METHODS: Therefore, 33,479 renal transplant recipients in the United States Renal Data System from 1 July 1, 1994 to June 30, 1997 were analyzed in an historical cohort study of patients with a primary discharge diagnosis of CMV disease (ICD9 Code 078.5x). RESULTS: Renal transplant recipients had an incidence density of hospitalized CMV disease of 1.26/100 person years, and 79% of hospitalizations for CMV disease occurred in the first six months post transplant. The leading manifestation of hospitalized infection was pneumonia (17%). In logistic regression analysis controlling for transplant era, pre-transplant dialysis > or = 6 months, maintenance mycophenolate mofetil (MMF) therapy, and allograft rejection, but not induction antibody therapy, were significantly associated with hospitalized CMV disease. Compared with recipients with negative CMV serology (R-) who had donor kidneys with negative CMV serology (D-), D+/R- had the highest risk of hospitalization for CMV disease [adjusted odds ratio (AOR) 5.19, 95% confidence interval (CI) 3.89-6.93] followed by D+/R+ recipients, whereas D-/R+ were not at significantly increased risk. In Cox Regression analysis the relative risk of death associated with hospitalized CMV disease was 1.32 (95% CI 1.02-1.71). CONCLUSIONS: Even in modern era, renal transplant recipients were at high risk for hospitalizations for CMV disease, which were associated with decreased patient survival. Current prophylactic measures have apparently not reduced the high risk of D+/R- recipients. Prolonged pre-transplant dialysis and maintenance MMF should also be considered risk factors for hospitalized CMV infection, and prospective trials of prophylactic antiviral therapy should be performed in these subgroups.


Subject(s)
Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/etiology , Hospitalization/statistics & numerical data , Kidney Transplantation , Adolescent , Adult , Aged , Antiviral Agents/therapeutic use , Cohort Studies , Cytomegalovirus Infections/prevention & control , Female , Humans , Immunosuppressive Agents/adverse effects , Incidence , Kidney Transplantation/adverse effects , Kidney Transplantation/immunology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Patient Readmission , Retrospective Studies , Risk Factors , United States/epidemiology
4.
J Nephrol ; 15(3): 255-62, 2002.
Article in English | MEDLINE | ID: mdl-12113596

ABSTRACT

PURPOSE: Bacterial pneumonia has been cited as the leading cause of infectious death in renal transplant recipients but has not been studied in a national transplant population. SUBJECT AND METHODS: Retrospective analysis of the incidence, risk factors and mortality of hospitalized bacterial pneumonia (ICD9 Code 481.x486.x) for 33,479 renal transplant recipients in the United States Renal Data System transplanted from 1 July 1994-30 June 1997. RESULTS: Among all transplant recipients, 4.7% were hospitalized for a primary discharge diagnosis of pneumonia in the study period (2.86 episodes per 100 person years). 9.9% had bronchoscopy and 4.8% had open lung biopsy. A specific etiology was not identified in 72.5% of patients. The hospitalization rate for pneumonia and hazard for mortality due to hospitalized pneumonia were both constant over time. In logistic regression analysis, pneumonia prior to transplant (odds ratio 1.73, 95% confidence interval, 1.32-2.26), older recipient age, diabetes, delayed graft function, rejection (occurring at any time after transplant during the time of the study), duration of pre-transplant dialysis, and positive recipient cytomegalovirus serology were associated with pneumonia. In Cox Regression, hospitalization for pneumonia was associated with greater risk of mortality (hazard ratio 1.64, 95% CI, 1.42-1.89). CONCLUSIONS: Renal transplant recipients with a previous history of pneumonia are at increased risk for subsequent pneumonia, which is associated with substantially decreased patient survival. Given the low rate of specific etiologies identified in this study, invasive diagnosis may be underutilized in this population.


Subject(s)
Hospitalization/statistics & numerical data , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/therapy , Kidney Transplantation/adverse effects , Kidney Transplantation/statistics & numerical data , Pneumonia, Bacterial/epidemiology , Pneumonia, Bacterial/etiology , Registries/statistics & numerical data , Aged , Female , Humans , Incidence , Length of Stay/statistics & numerical data , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Factors , Survival Rate , Time Factors , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...